Belova L, Tenson T, Xiong L, McNicholas P M, Mankin A S
Center for Pharmaceutical Biotechnology, M/C 870, University of Illinois, 900 South Ashland Avenue, Chicago, IL 60607, USA.
Proc Natl Acad Sci U S A. 2001 Mar 27;98(7):3726-31. doi: 10.1073/pnas.071527498. Epub 2001 Mar 20.
Evernimicin (Evn), an oligosaccharide antibiotic, interacts with the large ribosomal subunit and inhibits bacterial protein synthesis. RNA probing demonstrated that the drug protects a specific set of nucleotides in the loops of hairpins 89 and 91 of 23S rRNA in bacterial and archaeal ribosomes. Spontaneous Evn-resistant mutants of Halobacterium halobium contained mutations in hairpins 89 and 91 of 23S rRNA. In the ribosome tertiary structure, rRNA residues involved in interaction with the drug form a tight cluster that delineates the drug-binding site. Resistance mutations in the bacterial ribosomal protein L16, which is shown to be homologous to archaeal protein L10e, cluster to the same region as the rRNA mutations. The Evn-binding site overlaps with the binding site of initiation factor 2. Evn inhibits activity of initiation factor 2 in vitro, suggesting that the drug interferes with formation of the 70S initiation complex. The site of Evn binding and its mode of action are distinct from other ribosome-targeted antibiotics. This antibiotic target site can potentially be used for the development of new antibacterial drugs.
埃弗米星(Evn)是一种寡糖抗生素,它与核糖体大亚基相互作用并抑制细菌蛋白质合成。RNA探针实验表明,该药物可保护细菌和古细菌核糖体23S rRNA发夹结构89和91环中的一组特定核苷酸。嗜盐嗜盐菌的自发埃弗米星抗性突变体在23S rRNA的发夹结构89和91中存在突变。在核糖体三级结构中,与药物相互作用的rRNA残基形成一个紧密的簇,勾勒出药物结合位点。细菌核糖体蛋白L16中的抗性突变与古细菌蛋白L10e同源,这些突变聚集在与rRNA突变相同的区域。埃弗米星结合位点与起始因子2的结合位点重叠。埃弗米星在体外抑制起始因子2的活性,表明该药物干扰70S起始复合物的形成。埃弗米星的结合位点及其作用方式与其他核糖体靶向抗生素不同。这个抗生素靶点有可能用于开发新型抗菌药物。